Several clinical courses have been defined in multiple sclerosis (MS), but uncertainty remains as to whether they reflect different neuropathological mechanisms. Two recent concepts have emerged which could influence the treatment strategy adopted in MS:
- −inflammation drives axonal damage;
- −disability progression in MS follows a two-stage process.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the Neurological Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Defining the clinical course of multiple sclerosis: results of an international survey.Neurology. 1996; 46: 907-911
- Leçons sur les maladies du système nerveux faites à la Salpétrière.A Delahaye, Paris1880
- Axonal transection in the lesions of multiple sclerosis.N Engl J Med. 1998; 338: 278-285
- The relationship between inflammation and neurodegeneration in multiple sclerosis brains.Brain. 2009; 132: 1175-1189
- Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.Brain. 2008; 131: 808-817
- BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.Lancet. 2007; 370: 389-397
- BENEFIT Study Group. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.Lancet Neurol. 2009; 8: 987-997
- North American Study Group on Interferon beta-1b in secondary progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.Neurology. 2004; 63: 1788-1795
- Alemtuzumab vs interferon beta-1a in early multiple sclerosis.N Engl J Med. 2008; 359: 1786-1801
- The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.J Neurol. 2006; 253: 98-108
- Effect of relapses on development of residual deficit in multiple sclerosis.Neurology. 2003; 61: 1528-1532
- The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?.Ann Neurol. 2009; 65: 239-248
- Evidence for a two-stage disability progression in multiple sclerosis.Brain. 2010; 133: 1900-1913
Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M, et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomized trial. J Neurol Neurosurg Psychiatry (submitted for publication).
Published online: October 21, 2010
Accepted: September 20, 2010
Received in revised form: September 14, 2010
Received: June 17, 2010
© 2010 Elsevier B.V. Published by Elsevier Inc. All rights reserved.